Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
These drugs are approved to treat all six major genotypes of hepatitis C.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
This Ukrainian woman didn’t let outdated hepatitis C treatment or limited access to them, prevent her from getting necessary medical care.
Few people saw their liver disease progress, and there were scant numbers of relapses more than 12 weeks posttreatment in a large study.
In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.
This finding applies to those who begin treatment with progressive liver fibrosis, or scarring.
Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.
Such generic drugs could save nations huge sums in the coming years.
A promising new regimen that will address unmet needs for this population is poised for FDA approval.
The triple-drug regimen comes in a once-daily single tablet.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.